期刊
FREE RADICAL BIOLOGY AND MEDICINE
卷 122, 期 -, 页码 150-160出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.freeradbiomed.2018.02.004
关键词
Sulforaphane; Nrf2; NF kappa B; PPAR gamma; Type 1 diabetes; Type 2 diabetes; Cardiometabolic disease; Obesity; Diabetic nephropathy; Inflammasome
资金
- British Heart Foundation (BHF) [PG/17/38/33024, FS/10/59/28533]
Diabetes and cardiometabolic disorders such as hypertension and obesity are major risk factors for the development of cardiovascular disease, with a wealth of evidence suggesting that oxidative stress is linked to the initiation and pathogenesis of these disease processes. With yearly increases in the global incidence of cardiovascular diseases (CVD) and diabetes, numerous studies have focused on characterizing whether upregulating antioxidant defenses through exogenous antioxidants (e.g. vitamin E, vitamin C) or activation of endogenous defenses (e.g. the Nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant defense pathway) may be of benefit. The dietary isothiocyanate sulforaphane (SFN) is currently the subject of several clinical trials for a variety of disease states, including the evaluation of its therapeutic potential to ameliorate diabetic and cardiometabolic complications. SFN is a well characterized and potent Nrf2 inducer, however recent studies suggest its protective actions may be in part mediated by its modulation of various pro-inflammatory (e.g. Nuclear factor-kappa B (NF kappa B)) and metabolic (e.g. Peroxisome Proliferator-Activator Receptor Gamma (PPAR gamma)) signaling pathways. The focus of this review is to provide a detailed analysis of the known mechanisms by which SFN modulates Nrf2, NF kappa B and PPAR gamma signaling and crosstalk and to provide a critical evaluation of the evidence linking these transcriptional pathways with diabetic and cardiometabolic complications and SFN mediated cytoprotection. To allow comparison between rodent and human studies, we discuss the published bioavailability of SFN metabolites achieved in rodents and man in the context of Nrf2, NF kappa B and PPAR gamma signaling. Furthermore, we provide an update on the functional outcomes and implicated signaling pathways reported in recent clinical trials with SFN in Type 2 diabetic patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据